2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Non-Hodgkin Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

5371 Real-world management of JAK2 fusion-positive cutaneous T-cell lymphoma: Favorable outcomes with skin-directed therapy - a single-institution cohort and literature review.

Theresa Soojin Kim, BS, Viviane Liao, MD2, Tarek Bandali, MD3, Liam Carroll, MD4, Nivetha Ganesan, MPH5, Kendra Godwin, MLIS6, Cesar Virgen, MD, PhD7, Alison Moskowitz, MD8, Steven Horwitz, M.D.9, Paola Ghione, MD, MS10, Robert Stuver, MD11, Jasmine Zain, M.D.12, Zachary Epstein-Peterson, MD13, Andrea Moy, MD14, Melissa Pulitzer, MD15, Shamir Geller, MD16
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Stanford University, Stanford, California, United States
4 Oxford University Hospitals NHS Trust, Oxford, England, United Kingdom
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Background: Janus kinase 2 (JAK2) gene fusions were initially identified in aggressive cutaneous T-cell lymphoma (CTCL) subtypes, but recent studies have also reported them in early-stage and indolent CTCL, raising questions about their prognostic significance and therapeutic relevance. Few data exist regarding management, long-term outcomes, and the role of systemic therapies in this subgroup. We sought to evaluate the management and treatment outcomes, including response to JAK inhibitor therapies.

Methods: We retrospectively reviewed real-world clinical data on outcome, treatment and responses for 62 CTCL patients with JAK2 gene fusions identified between 2000-2025. Forty-five cases were diagnosed as mycosis fungoides (MF), 3 CD30+ lymphoproliferative disorders (LPD) and 8 overlap MF/CD30LPD, five had primary cutaneous CD8+ aggressive epidermotropic T-cell lymphoma (pcAETCL) and 1 peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Gene fusions were identified by MSK ArcherTM based fusion Heme panel and MSK-Integrated Mutation Profiling of Actionable Cancer Targets for Hematologic Malignancies (MSK-IMPACT-Heme) with most common fusion partners being ATXN2L (n=15), PCM1 (12), CAPRIN1 (8), and STAT3 (7). Given the retrospective design, response assessment was based on documentation available in the clinical notes rather than standardized response criteria. In addition, we performed a comprehensive literature review of all reported adult CTCL cases with JAK2 fusions and summarized the reported treatments and outcomes.

Results: Sixty-two CTCL patients with JAK2 gene fusions had a median follow-up of 21.3 months [range 0.3-155.9] at our institution. Twenty-one patients (33.9%) received systemic therapy including 13 patients who had advanced disease at time of diagnosis (6 with advanced MF [stage IIB, IIIA, IVA], 5 pcAETCL, 1 MF/CD+30LPD, 1 PTOS-NOS) and 8 patients who had indolent disease (6 early-stage MF, 1 CD30+LPD, 1 MF30+/LPD overlap). Forty-one patients with indolent disease were managed with skin-directed therapies alone. At last follow-up, most achieved complete/near-complete response (12/41) or stable disease (20/41), whereas partial response (8/41) and disease progression (1/41) were less common. Four patients received topical ruxolitinib, a kinase inhibitor with selectivity for JAK1 and JAK2, after JAK2 gene fusion identification; at last follow-up, 2 showed a response and 2 had stable disease. Two additional patients had been treated with topical ruxolitinib before fusion detection and were switched to other therapies due to insufficient response. Treatment patterns varied by fusion partner, with skin-directed therapies alone being most common among cases harboring ATXN2L (13/15), PICALM (5/5), and CLTC (2/2) fusion partners to JAK2.

In a comprehensive literature review, 8 publications from 2017-2025 reported 16 adult CTCL patients with JAK2 gene fusions (8 pcAETCL, 1 primary cutaneous gamma/delta T-cell lymphoma (PCGDTCL), 2 MF, and diagnosis was not available in 5). PCM1 was the most common fusion partner (n=6) and occurred in both aggressive and indolent CTCL. Only 3 cases included management and outcome data; all of which required systemic therapy after progression on skin-directed treatment. Two of these cases started as early stage/indolent disease (IL3 and PCM1 partners) and one was diagnosed with PCGDTCL (PCM1). Oral ruxolitinib was reported in the PCGDTCL case, but the patient died of progressive disease.

Conclusion: JAK2 gene fusions span the clinical spectrum of CTCL and are not predictive of aggressive behavior. Most patients in our cohort had early-stage disease and an indolent course that was managed with skin-directed therapy alone. Additionally, majority of patients who required systemic treatment were those who had an aggressive CTCL subtype to begin with. These findings argue against initiating systemic therapies based on fusion status alone. Given the biological rationale for targeting the JAK-STAT pathway, future and ongoing studies are needed to further investigate the efficacy of JAK inhibitors for CTCL patients with JAK2 gene fusions.
Shamir Geller, MD: No relevant conflicts of interest to declare.